Description
INDICATION
It is indicated for:
The treatment of nocturia associated with multiple sclerosis.
The diagnosis and treatment of vasopressin−sensitive cranial diabetes insipidus.
Establishing renal concentration capacity.
DOSAGE
Treatment of Nocturia associated with multiple sclerosis:
For multiple sclerosis patients up to 65 years of age with normal renal function suffering from nocturia the dose is one or two sprays intranasally (10 to 20 micrograms) at bedtime. Not more than one dose should be used in any 24 hour period. If a dose of two sprays is required, this should be as one spray into each nostril.
Treatment of Diabetes Insipidus:
Dosage is individual but clinical experience has shown that the average maintenance dose in adults and children is one or two sprays (10 to 20 micrograms) once or twice daily. If a dose of two sprays is required, this should be as one spray into each nostril.
Diagnosis of Diabetes Insipidus:
The diagnostic dose in adults and children is two sprays (20 micrograms). Failure to elaborate concentrated urine after water deprivation, followed by the ability to do so after the administration of Desmospray confirms the diagnosis of cranial diabetes insipidus. Failure to concentrate after the administration suggests nephrogenic diabetes insipidus.
Renal Function Testing:
To establish renal concentration capacity, the following single doses are recommended.
Adults: Two sprays into each nostril (a total of 40 micrograms).
Children: (1−15 years): One spray into each nostril (a total of 20 micrograms).
Infants (to 1 year): One spray (10 micrograms).
Adults and children with normal renal function can be expected to achieve concentrations above 700mOsm/kg in the period of 5−9 hours following administration of Desmospray. It is recommended that the bladder should be emptied at the time of administration.
Fluid restriction should be observed in all the above cases.
PREGNANCY AND LACTATION
Consult a physician before using the medication in the case of pregnant and breastfeeding women.
SIDE EFFECTS
headache, nausea, vomiting, decreased serum sodium, weight increase, malaise, abdominal pain, muscle cramps, dizziness, confusion, decreased consciousness and in severe cases convulsions and coma
ACTIVE INGREDIENT
desmopressin acetate
